Hospital Universitario de Jaén

Jaén 23007

5 studies enrolling now · 8 studies all time

What they study most

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, Breast Cancer, Breast Carcinoma, Carcinoma, Hepatocellular, Cardiovascular Diseases, Colorectal Neoplasms, Diabetes Mellitus, Type 2, Endometrial Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hypertension, Liver Neoplasms, Metastatic Breast Cancer

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects — Recruiting now
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — Recruiting now
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence — Recruiting now
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients — Recruiting now
• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) — Running, not enrolling
• Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy — Stopped early
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor — Running, not enrolling